A better COVID treatment for the immunocompromised? Researchers create a non-toxic potential alternative to Paxlovid
A combination of two antiviral compounds may be a promising alternative to Paxlovid when treating COVID-19 in ...
Hoodline5h
Paxlovid, An Underutilized Defense Against COVID-19's Grip, Critical for High-Risk Groups
The FDA-approved antiviral Paxlovid is underused for high-risk COVID-19 patients, despite its efficacy in preventing severe illness.
Can nasal Neosporin fight COVID? Surprising new research suggests it works
A potential treatment for COVID-19 may have been hiding in our medicine cabinets, a new study in PNAS has found ...
Pfizer lifts profit view on cost cuts, demand for COVID products
Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, ...
KFGO6d
Pfizer lifts 2024 profit view on cost cuts, higher COVID vaccine demand
Pfizer lifted its annual profit forecast on Wednesday, banking on cost cuts and better-than-expected demand for its COVID ...
Could Avian Influenza Be The Next Covid-19?
H5N1 has been detected in over 9,000 wild birds, 90 million poultry and in dairy cattle. A recent human case in Texas has ...
Pfizer lifts profit forecast on cost cuts, smaller drop in Covid drug demand
Pfizer lifted its annual profit forecast on Wednesday, and reported first-quarter results that topped Wall Street estimates ...
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
(NYSE American:NNVC) (the 'Company'), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes Influenza A viruses, possibly ...
Mint5d
Pfizer lifts profit forecast as CEO sees reason for optimism in 2024
boosted by cost cutting efforts and stronger-than-expected sales of its COVID antiviral treatment. Sales of Padcev, a treatment for advanced bladder cancer Pfizer gained through its $43 billion ...